These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 29124482)

  • 1. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
    Rocha NA; East C; Zhang J; McCullough PA
    Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Volanesorsen: First Global Approval.
    Paik J; Duggan S
    Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen.
    Zhang J; Rocha NA; McCullough PA
    Rev Cardiovasc Med; 2018 Mar; 19(1):13-19. PubMed ID: 31032598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results.
    Yang X; Lee SR; Choi YS; Alexander VJ; Digenio A; Yang Q; Miller YI; Witztum JL; Tsimikas S
    J Lipid Res; 2016 Apr; 57(4):706-13. PubMed ID: 26848137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Apolipoprotein CIII trials.
    Tramontano D; Bini S; D'Erasmo L; Arca M
    Curr Opin Lipidol; 2022 Dec; 33(6):309-318. PubMed ID: 36206093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
    D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
    Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volanesorsen for treatment of patients with familial chylomicronemia syndrome.
    Warden BA; Duell PB
    Drugs Today (Barc); 2018 Dec; 54(12):721-735. PubMed ID: 30596391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ApoCIII: the next PCSK9?
    Bernelot Moens SJ; van Capelleveen JC; Stroes ES
    Curr Opin Lipidol; 2014 Dec; 25(6):418-22. PubMed ID: 25255477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials.
    Fogacci F; Norata GD; Toth PP; Arca M; Cicero AFG
    Curr Atheroscler Rep; 2020 May; 22(5):18. PubMed ID: 32458077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
    Schmitz J; Gouni-Berthold I
    Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen: A case report.
    Tünnemann-Tarr A; Scharnagl H; Katzmann JL; Stürzebecher P; Laufs U
    Medicine (Baltimore); 2021 Oct; 100(42):e27573. PubMed ID: 34678899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein CIII links dyslipidemia with atherosclerosis.
    Kawakami A; Yoshida M
    J Atheroscler Thromb; 2009 Mar; 16(1):6-11. PubMed ID: 19262004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein CIII and diabetes. Is there a link?
    Christopoulou E; Tsimihodimos V; Filippatos T; Elisaf M
    Diabetes Metab Res Rev; 2019 Mar; 35(3):e3118. PubMed ID: 30557902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease.
    Zheng C
    Curr Opin Lipidol; 2014 Feb; 25(1):35-9. PubMed ID: 24345989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ApoCIII: A multifaceted protein in cardiometabolic disease.
    D'Erasmo L; Di Costanzo A; Gallo A; Bruckert E; Arca M
    Metabolism; 2020 Dec; 113():154395. PubMed ID: 33058850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
    Witztum JL; Gaudet D; Freedman SD; Alexander VJ; Digenio A; Williams KR; Yang Q; Hughes SG; Geary RS; Arca M; Stroes ESG; Bergeron J; Soran H; Civeira F; Hemphill L; Tsimikas S; Blom DJ; O'Dea L; Bruckert E
    N Engl J Med; 2019 Aug; 381(6):531-542. PubMed ID: 31390500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
    Chaudhry R; Viljoen A; Wierzbicki AS
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
    Taskinen MR; Packard CJ; Borén J
    Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etiology and emerging treatments for familial chylomicronemia syndrome.
    Spagnuolo CM; Hegele RA
    Expert Rev Endocrinol Metab; 2024 Jul; 19(4):299-306. PubMed ID: 38866702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.